直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

En Banc Court Reaffirms Patentees’ Right to Place Lawful Restrictions on Sales of Patented Articles and International Sales Constitute Infringement When Imported Into the United States

February 12, 2016

Authored and Edited by Kevin D. Rodkey; Elizabeth D. Ferrill

The doctrine of patent exhaustion limits a patentee’s ability to control the use of patented articles after an authorized sale of those articles. In Lexmark International, Inc. v. Impression Products, Inc., Nos. 14-1617, -1619 (Fed. Cir. Feb. 12, 2016), a majority of the en banc Federal Circuit reaffirmed its prior decisions in Mallinckrodt v. Medipart, 976 F.2d 700 (Fed. Cir. 1992) and Jazz Photo Corp. v. International Trade Commission, 264 F.3d 1094 (Fed. Cir. 2001) on two issues of patent exhaustion: post-sale limits on use and resale and whether foreign sales exhaust a patentee’s U.S. rights.

Post-sale limits on use and resale

In reaffirming Mallinckrodt, the court held that a patentee may preserve its right to allege infringement when selling a patented article through “clearly communicated, otherwise-lawful restrictions.” Specifically, the court upheld that a patentee has the ability to “sell[] a patented article subject to a single-use/no-resale restriction that is lawful and clearly communicated to the purchaser” without exhausting the patentee’s rights in that item.

The court rejected Impression’s and the government’s argument that any sale by a patentee automatically exhausts the patentee’s rights to the article sold. Rather, the court analogized the issue to a licensor limiting the rights of a licensee, and explained that patent rights were not exhausted “simply because [the patentee] sold the [patented articles] itself..., rather than having left the manufacture and sale to others under [a] license.” The court also distinguished the Supreme Court’s holding in Quanta v. LG Electronics, 553 U.S. 617 (2008), because Quanta decided the issue of an unrestricted sale that was not subject to any conditions, but “did not involve a patentee’s sale” or single-use/no-resale restriction applied by Lexmark. Examining the “longstanding Supreme Court precedent” that a patentee may preserve its patent rights against downstream buyers through lawful restrictions on licensees, the court concluded that “the law does not forbid the patentee to do the same when making and selling the articles itself.”

Foreign sales and exhaustion a patentee’s U.S. rights

In reaffirming Jazz Photo, the court also held that importing patented articles sold abroad constitutes infringement, unless the patentee has authorized the importation, because foreign sales do “not authorize the buyer to import the article and sell and use it in the United States.”

Distinguishing the Supreme Court’s recent decision in Kirtsaeng v. John Wiley & Sons, 133 S. Ct. 1351 (2013), which analyzed foreign sales under section 109 of the Copyright Act, the Federal Circuit determined that Kirtsaeng “does not answer the question presented under the Patent Act.” In particular, the court considered the distinctions between the Patent Act and the Copyright Act, such as a patentee’s right to exclude another’s “use,” which a copyright holder does not have. The court distinguished the statutory text analyzed in Kirtsaeng as referring the location of manufacture, but not “whether a foreign sale...is properly treated as conferring on the buyer...the authority to resell” the article. After concluding that Kirtsaeng did not control the outcome, the court held that a patentee does not waive its U.S. rights to a patented article “simply by making or authorizing a foreign sale of an article.” The court explained, however, that U.S. patent rights may be exhausted by a foreign sale under an express or implied license, but that that question was not presented here.

Dissenting opinion

Judge Dyk, joined by Judge Hughes, dissented and would have found that Mallinckrodt “was wrongly decided” and “cannot be reconciled with [Quanta],” and that foreign sales would “result in exhaustion if an authorized seller has not explicitly reserved the United States patent rights.”

Tags

post-sale restrictions

Related Practices

Diligence, Licensing, and Opinions

Licensing, Pooling, and Other Transactions

Contacts

Kevin D. Rodkey
Partner
Atlanta, GA
+1 404 653 6484
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP